Abbott Laboratories announced positive results from the first human trial of its ZoMaxx stent, which is a drug-coated device to open clogged arteries and prevent them from being clogged again, making the company a major player in the business of unclogging arteries to the heart. The study showed the stent to be safe and effective, and patients suffered "no major adverse cardiac events."

Related Summaries